What is Speclipse?
Established in 2015 and co-headquartered in Sunnyvale, California, and Seoul, South Korea, Speclipse is a pioneering company recognized globally for its technological advancements in diagnostics. Founded by Sung Hyun Pyun, a Stanford University graduate and former Boston Consulting Group consultant, Speclipse initially focused on skin cancer diagnostics. The company has since expanded its scope to include blood analysis, demonstrating a strategic pivot towards broader diagnostic capabilities. Its selection as a Dermatology Solution Provider by Medtech Outlook highlights its significant impact and innovation within the US healthcare professional community, positioning it as a key player in the medical technology landscape.
How much funding has Speclipse raised?
Speclipse has raised a total of $7.7M across 1 funding round:
Unspecified
$7.7M
Unspecified (2021): $7.7M with participation from Signite Partners, MiCoBioMed, BNH Investment, MiCo, and Shinhan Capital
Key Investors in Speclipse
Signite Partners
Signite Partners is an investor participating in the funding round, with their specific investment focus yet to be disclosed.
MiCoBioMed
MiCoBioMed is an investor participating in the funding round, with their specific investment focus yet to be disclosed.
BNH Investment
BNH Investment is an investor participating in the funding round, with their specific investment focus yet to be disclosed.
What's next for Speclipse?
The recent major strategic investment signals Speclipse's readiness for accelerated scaling and market penetration. With a foundation built on cutting-edge diagnostics for skin cancer and an expanding portfolio into blood analysis, the company is well-positioned to leverage this capital for further research and development, potential market expansion, and strategic partnerships. This infusion of financing is expected to bolster its technological infrastructure and support its transition into a more comprehensive healthcare solutions provider, potentially leading to new product launches and increased market share in the global diagnostics arena.
See full Speclipse company page
